VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
2.020
+0.030 (1.51%)
At close: Feb 20, 2026, 4:00 PM EST
2.089
+0.068 (3.39%)
After-hours: Feb 20, 2026, 7:48 PM EST
VivoSim Labs Employees
VivoSim Labs had 14 employees as of December 31, 2025. The number of employees did not change compared to the same quarter last year.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
$10,143
Profits / Employee
-$87,643
Market Cap
5.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - | 14 | 0 |
| Sep 30, 2025 | 13 | -6 | -31.58% | 13 | 0 |
| Jun 30, 2025 | 13 | -7 | -35.00% | 13 | 0 |
| Mar 31, 2025 | 13 | -7 | -35.00% | 5 | 8 |
| Dec 31, 2024 | 14 | -4 | -22.22% | 14 | 0 |
| Sep 30, 2024 | 19 | -4 | -17.39% | 19 | 0 |
| Jun 30, 2024 | 20 | -3 | -13.04% | 20 | 0 |
| Mar 31, 2024 | 20 | -4 | -16.67% | 12 | 8 |
| Dec 31, 2023 | 18 | -2 | -10.00% | 18 | 0 |
| Sep 30, 2023 | 23 | 3 | 15.00% | 23 | 0 |
| Jun 30, 2023 | 23 | 4 | 21.05% | 23 | 0 |
| Mar 31, 2023 | 24 | 6 | 33.33% | 15 | 9 |
| Dec 31, 2022 | 20 | 8 | 66.67% | 20 | 0 |
| Sep 30, 2022 | 20 | 9 | 81.82% | 20 | 0 |
| Jun 30, 2022 | 19 | 10 | 111.11% | 19 | 0 |
| Mar 31, 2022 | 18 | 9 | 100.00% | 9 | 9 |
| Dec 31, 2021 | 12 | 5 | 71.43% | 12 | 0 |
| Sep 30, 2021 | 11 | 5 | 83.33% | 11 | 0 |
| Jun 30, 2021 | 9 | 3 | 50.00% | 9 | 0 |
| Mar 31, 2021 | 9 | 3 | 50.00% | 4 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 28 |
| Genprex | 13 |
| Processa Pharmaceuticals | 10 |
| MetaVia | 9 |
| Aprea Therapeutics | 8 |
| Acurx Pharmaceuticals | 4 |
| Decoy Therapeutics | 2 |
| Xenetic Biosciences | 2 |
VIVS News
- 9 days ago - VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego - GlobeNewsWire
- 22 days ago - VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China - GlobeNewsWire
- 6 weeks ago - VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer - GlobeNewsWire
- 6 months ago - VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer - GlobeNewsWire
- 9 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 10 months ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 10 months ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire
- 10 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire